In the Virus-Like Particle Translational Oncology Laboratory, Qizhi Cathy Yao, M.D., Ph.D. is developing non-infectious HIV virus-like particles (VLPs) as candidate HIV mucosal vaccines for both ...
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer and Shionogi as shareholders, today announced an exclusive ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...
HIV-1 protease inhibitors are unique among anti-HIV-1 drugs in that they have very high potency and they also have a very high genetic barrier to resistance. The viral protease is essential in the ...
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of 64 abstracts that ...
The finding provides further evidence that antibodies—specialized proteins that the body produces to fight infections—could one day be used as a method to prevent people from becoming infected with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results